On February 23, 2024, Abbisko Therapeutics announced that its independently developed new-generation EGFR Exon20ins inhibitor ABSK112 has completed the first patient administration in its Phase I clinical trial for non-small cell lung cancer (NSCLC).

Previously, ABSK112 has obtained clinical research licenses from China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), and is conducting Phase I clinical trials simultaneously in China and the United States.

ABSK112 is a new generation of EGFR Exon20ins oral inhibitor with high activity, high selectivity and brain entry properties. Compared with the previous generation of EGFR Exon20ins inhibitors that have been on the market or entered clinical trials, ABSK112 has demonstrated better brain entry properties, high selectivity against wild-type EGFR, and broader Exon20ins mutation coverage in preclinical studies. It has shown excellent in vivo efficacy in multiple mouse tumor models with EGFR Exon20ins mutations. It has the potential to obtain a better therapeutic window and efficacy in clinical practice and become a new generation of best-in-class drugs.

About NSCLC

Lung cancer is the second most common cancer in the world, with more than 2 million new cases in 2020, including 227,875 cases in the United States and 815,563 cases in China. Lung cancer ranks first in mortality, with more than 1.7 million deaths every year, including 138,225 cases (7.7%) in the United States and 714,699 cases (39.8%) in China. Non-small cell lung cancer (NSCLC) accounts for the highest proportion (85%) of all lung cancers. Epidermal growth factor receptor (EGFR) mutations occur in approximately 17% and 50% of lung adenocarcinomas in Caucasians and Asians, respectively. In NSCLC patients, EGFR Exon20ins mutations account for approximately 1%-12% of EGFR mutations.

https://news.yaozh.com/archive/41959.html